Phase 3 Recruiting Industry
The purpose of this study is to learn more about a new medicine called PF-08634404, and how well it works in people with cancer of the colon or rectum (CRC)). The goal is to understand if the new study medicine, combined with chemotherapy …
Sponsor: Pfizer
NCT ID: NCT07222800
Sites in Indiana: - Franciscan Health — Indianapolis, Indiana
- Franciscan Health Mooresville — Mooresville, Indiana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Sponsor: Incyte Corporation
NCT ID: NCT07284849
Sites in Indiana: - Community Health Network, Inc. — Indianapolis, Indiana
- Hematology Oncology of Indiana — Indianapolis, Indiana
Phase 3 Recruiting Network
This phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the li…
Sponsor: ECOG-ACRIN Cancer Research Group
NCT ID: NCT05863195
Sites in Indiana: - IU Health North Hospital — Carmel, Indiana
- Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 2 Recruiting Industry
TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.
Sponsor: AstraZeneca
NCT ID: NCT05489211
Sites in Indiana: - Research Site — Muncie, Indiana
Phase 1, Phase 2 Recruiting Industry
The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will be conducted in 3 parts: Phase 1A (Dose Escalation), Phase 1B (Dose Expansion), and Phase …
Sponsor: Frontier Medicines Corporation
NCT ID: NCT06244771
Sites in Indiana: - Northwest Cancer Centers — Dyer, Indiana
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2A study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Sponsor: GV20 Therapeutics
NCT ID: NCT05669430
Sites in Indiana: - Community Health Network, Inc. — Indianapolis, Indiana
Phase 2 Recruiting Academic/Other
A single arm phase II study of pembrolizumab, carboplatin, paclitaxel, and radiation for the treatment of early-stage anal cancer. There are 2 treatments phases and then surveillance. The first treatment phase is the chemoradiation phase (…
Sponsor: Dustin Deming
NCT ID: NCT06493019
Sites in Indiana: - Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Indiana: - Exelixis Clinical Site #4 — Indianapolis, Indiana
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Indiana: - Indiana University — Indianapolis, Indiana
Phase 1 Recruiting Industry
The main purpose of this study is to assess safety \& tolerability and antitumor activity of LY3962673 as monotherapy and in combination with other chemotherapy agents in participants with KRAS G12D-mutant advanced solid tumor types. The s…
Sponsor: Eli Lilly and Company
NCT ID: NCT06586515
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 1 Recruiting Industry
This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). The purpose of this study is …
Sponsor: Eli Lilly and Company
NCT ID: NCT07213791
Sites in Indiana: - Indiana University (IU) School of Medicine — Indianapolis, Indiana
Phase 1 Recruiting Industry
First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other anti-cancer agents in patients with advanced solid tumors.
Sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
NCT ID: NCT06625775
Sites in Indiana: - Indiana University Simon Comprehensive Cancer Center — Indianapolis, Indiana
Phase 1 Recruiting Industry
The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with …
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06663319
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Indiana: - Reid Health — Richmond, Indiana
NA Recruiting Academic/Other
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Sponsor: NRG Oncology
NCT ID: NCT05080673
Sites in Indiana: - Northwest Cancer Center - Crown Point — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
- Northwest Cancer Center - Hobart — Hobart, Indiana
- Saint Mary Medical Center — Hobart, Indiana
- Saint Catherine Hospital — Indianapolis, Indiana
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Indiana: - Woodland Cancer Care Center — Michigan City, Indiana
- Reid Health — Richmond, Indiana
NA Recruiting Academic/Other
This clinical trial compares patient (proband)-mediated communication to provider-mediated communication for improving genetic testing in first-degree relatives of patients with newly diagnosed colorectal cancer. It is estimated that 30% o…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07143487
Sites in Indiana: - Reid Health — Richmond, Indiana
Recruiting Academic/Other
This study evaluates cancer-related weight and muscle mass loss, symptoms, and physical function (cachexia) in patients undergoing treatment for colorectal, lung, or pancreatic cancer that cannot be removed by surgery (unresectable) or is …
Sponsor: University of Rochester
NCT ID: NCT06073431
Sites in Indiana: - Reid Health — Richmond, Indiana
Phase 4 Recruiting Industry
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory me…
Sponsor: Takeda
NCT ID: NCT06562543
Sites in Indiana: - Indiana University — Indianapolis, Indiana
NA Recruiting Academic/Other
This is a multi-site comparative effectiveness randomized controlled trial (RCT) comparing annual fecal immunochemical testing (FIT) and colonoscopy for post-polypectomy surveillance among adults aged 65-82 with a history of colorectal pol…
Sponsor: Dartmouth-Hitchcock Medical Center
NCT ID: NCT05612347
Sites in Indiana: - Richard L. Roudebush VA Medical Center — Indianapolis, Indiana
Recruiting Industry
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types. The cancers included in this study are brain, breast, …
Sponsor: Adela, Inc
NCT ID: NCT05366881
Sites in Indiana: - Baptist Floyd — New Albany, Indiana
NA Recruiting Academic/Other
Germline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network aims to evaluate the impact of a suite o…
Sponsor: Josh Peterson
NCT ID: NCT07307664
Sites in Indiana: - Indiana University School of Medicine — Indianapolis, Indiana
NA Recruiting Academic/Other
The goal of this clinical trial is to learn if changing cysteine levels in the diet can influence how the body processes cysteine in Black and White individuals aged 45-75 with a history of non-cancerous polyps. The main questions it aims …
Sponsor: Purdue University
NCT ID: NCT07086833
Sites in Indiana: - University Hospital Clinical Research Center — Indianapolis, Indiana
- Purdue Clinical Research Center — West Lafayette, Indiana
Recruiting Academic/Other
The purpose of this research study is to see how the brain changes in patients receiving chemotherapy (cytotoxic drug) treatment for colon or rectal cancer at Parkview Cancer Institute. This information will be used to identify helpful tes…
Sponsor: Joseph McCollom
NCT ID: NCT05014399
Sites in Indiana: - Parkview Cancer Institute — Fort Wayne, Indiana